The permeability transition pore (PTP) is a multi-protein complex at contact sites of the inner with the outer mitochondrial membrane. Research over the past years has led to the concept that the PTP occupies a central role in cell death induction. Numerous apoptosis signals convert this protein aggregate into an unspecific pore, thus activating mitochondria for the cellular self-destruction process. Here, we describe the evidence for this and the various approaches being undertaken to elucidate its subunit composition and mode of regulation. In particular, we review data that indicate a role of specific PTP subunits for apoptosis inhibition during tumorigenesis.
Introduction to the permeability transition pore: friend and foe Discovery of permeability transition pore: Ca 2 þ , cyclosporin A and matricial swelling The pioneer work of Hunter et al. (1976) on calcium (Ca 2 þ )-treated isolated mitochondria led to the proposal of the concept of permeability transition (PT). Accordingly, Ca 2 þ induced a configurational transition of mitochondria from an aggregated to an orthodox state and a simultaneous uncoupling of oxidative phosphorylation. Moreover, they demonstrated that Ca 2 þ , as well as phosphate, arsenate or oleic acid, causes a nonspecific increase in the permeability of the inner membrane (IM), resulting in entry of sucrose into the matrix space, its swelling and the transition (Hunter et al., 1976) . The process was also detected in mitochondria of various tissue origins in response to numerous stimuli, and was also observed in several pathologies, such as cardiac, brain and hepatic ischemia/reperfusion insults in vivo (Bernardi, 1996; Friberg and Wieloch, 2002; Halestrap et al., 2004; Le Bras et al., 2005) .
The discovery of the existence of a large conductance channel responsible for PT was primarily based on electrophysiological studies applied to rat liver mitoplasts (Petronilli et al., 1989) . This giant channel, also called megachannel or permeability transition pore (PTP), mediated high conductances, which were inhibited by cyclosporin A (CsA), Mg 2 þ and adenosine diphosphate (ADP) in the same range as that used in isolated mitochondria to inhibit Ca 2 þ effects (Broekemeier et al., 1989; Zoratti, 1991, 1992) . Thus, Zoratti and Szabo proposed that the megachannel detected in patch-clamp experiments is the channel responsible for the Ca 2 þ -dependent PT in isolated mitochondria. Application of increasing voltages of either polarity revealed the presence of several different conductances, ranging from 0.3 to 1.3 nS. This suggested that conductances around 0.3 nS are substates of the highest conductance channel and plausibly would result from the assembly of different subunits of unknown identity.
Several independent studies addressed the question of the protein composition of PTP. Various soluble and membrane proteins including the voltage-dependent anion channel (VDAC), the adenine nucleotide translocase (ANT), peripheral benzodiazepine receptor (PBR), creatine kinase (CK), hexokinase (HK) and/or cyclophilin D (CypD) have been found (Beutner et al., 1996b; Crompton et al., 1998) (Figure 1 ). Although the workers agreed on the localization of the pore in the contact sites of IM and outer membrane (OM) in mitochondria (Brdiczka, 1991; Crompton, 2000) , the precise composition of PTP is still under intense debate. Notably, the respective contribution of ANT and CypD to the PTP has recently been questioned in several studies conducted in mice that have been engineered to deplete these proteins (Kokoszka et al., 2004; Baines et al., 2005; Nakagawa et al., 2005 ) (see below). Adenine nucleotide translocase, a major candidate for the IM pore, has been isolated in several protein subcomplexes composed of various ratios of VDAC and CypD (for a review, see Crompton et al., 2002; Faustin et al., 2004) , as well as in a complex with the F0F1-ATPase and the phosphate carrier (Ko et al., 2003) . The state of protein oligomerization might depend on the respiratory rate of mitochondria (Faustin et al., 2004) , rendering the isolation of a unique complex a challenge. However, a consensus emerged to consider the PTP as a multiprotein complex of about 600 kDa (Beutner et al., 1996a; Faustin et al., 2004) . Its components could be involved in several subcomplexes, dedicated to the maintenance of the energetic metabolism and/or to the execution of cell death (Crompton et al., 2002; Zoratti et al., 2005) .
Dual role of permeability transition pore Permeability transition pore in normal physiology: transport of metabolites. To achieve their multiple functions in normal physiology such as the generation of an IM electrochemical potential (DC m ), the biosynthesis of molecules and the transport of metabolic and/or structural molecules, mitochondria have to be tightly controlled. If these functions are not correctly regulated, mitochondria could undergo irreversible damage and be eliminated by autophagy (Elmore et al., 2001) . Thus, one of the basic functions of PTP is to regulate the fluxes of ADP/adenosine 5 0 triphosphate (ATP) between the matrix, the intermembrane space and the cytosol by a process termed the ATP channeling. Adenine nucleotide translocase allows the matricial ATP to be exported to the intermembrane space in an electrogenic process, and subsequently to the cytosol via VDAC. In response to the energetic demand of the subcompartments, ADP and ATP can be used by adenylate kinase, CK and/or HK to phosphorylate their respective substrates.
In some circumstances, PT is also dedicated to the control of mitochondrial homeostasis via a sudden increase of the IM permeability to protons, water and solutes of M r o1500 Da, allowing a balance between the composition and the state of the matrix and the cytosol. Adenine nucleotide pools, the intra-matricial pH, the DC m and the redox state regulate this physiological function of PT (Halestrap et al., 1997b) . Of note, this implies that alterations of proteic effectors such as PTP (e.g. by oxidative stress) can influence the cell fate via the alteration of the physiological function of PT. This can be the case in chronic as well as in acute pathologies, including aging, neurodegenerative diseases, diabetes mellitus, vascular diseases, cell transformation and carcinogenesis (for a review, see Le Bras et al., 2005) . Thus, the enforced opening of PTP as well as its prolonged closing is believed to be deleterious to the cell. For instance, it has been shown that CsA (a pore inhibitor) and PK11195 (a pore opener sensitizer) can facilitate the mitochondrial apoptosis induced by a natural polyphenol, resveratrol, via the modulation of PT (Zunino and Storms, 2005) .
Permeability transition pore in apoptosis/necrosis: an unspecific pore. The involvement of PT in cell death results primarily from pharmacological studies conducted on isolated mitochondria and from measurements of the DC m in cells by flow cytometry (Vayssiere et al., 1994; Petit et al., 1995; Zamzami et al., 1995; Marchetti et al., 1996) . Thus, PT can be favored or prevented by endogenous molecules as well as xenobiotics in a direct manner (for reviews, see Vieira et al., 2000; Belzacq et al., 2002) . The proapoptotic molecules range from calcium to pro-oxidant agents (e.g. tertbutylhydroperoxide (t-BHP), diamide and phenylarsine oxide) (Costantini et al., 2000; Vieira et al., 2001) , small molecules (e.g. atractyloside (Atr), arsenate (Larochette et al., 1999) , PK11195 (Hirsch et al., 1998a) , GD3 ganglioside (Scorrano et al., 1999) and peptides (e.g. mastoparan (Pfeiffer et al., 1995) , viral protein R 52-96 (Vpr 52-96) ) and BH3-Bax Figure 1 The permeability transition pore (PTP) function. During apoptosis, many signals can converge on the mitochondrion to regulate the mitochondrial membrane permeability. In response to calcium (Ca 2 þ ), atractyloside, adenine nucleotide depletion, chemotherapeutics and pro-oxidant agents, the membrane permeabilization can result from the opening of PTP as a large unspecific channel and leads to the release of proapoptotic factors into the cytosol. In contrast, many agents (CsA, bongkrekic acid, Mg 2 þ , high ADP/ATP) or conditions (pHo7) promote the closure of the PTP and prevent apoptosis. When available, PDB structure models for PTP members have been inserted. delays PT such as CsA and sanglifehrin A, two CypD ligands (Halestrap et al., 1997a; Clarke et al., 2002) , bongrekic acid (BA), ADP and ATP, ligands of the ANT (Halestrap, 2004) ; 4,4 0 -diisothiocyanatostilbene-2,2 0 -disulfonic acid, DIDS, and NADH, VDAC channel blockers (Shoshan-Barmatz and Gincel, 2003) , and Bcl-2 and Bcl-X L , oncoproteins (for a review, see Zamzami et al., 1998) . Anti-oxidants such as glutathione (GSH), catalase, superoxide dismutase have also proven to be capable of preventing PT, notably when induced by chemicals and neurotoxins Haouzi et al., 2002) .
Once PT is initiated, depolarized mitochondria undergo a massive entry of water favoring matrix swelling, remodeling of cristae and -owing to the difference of surface between IM and OM -local ruptures of the OM (Vander Heiden et al., 1997) . These events are accompanied by the release of proapoptotic proteins into the cytosol, such as cytochrome c and apoptosis-inducing factor, AIF (for a review, see Green and Kroemer, 2004) . The occurrence of PT in intact cells was demonstrated by methods of PT imaging Petronilli et al., 1999) . These methods are based on the loading of hepatocytes with a fluorescent probe such as calcein and cobalt (Co 2 þ ), its quencher. When added onto cells, the probe distributes within all compartment in the cell, whereas Co 2 þ cannot diffuse into mitochondria owing to the impermeability of its membrane Petronilli et al., 1999) . Thus, under physiological conditions, mitochondria fluoresce, whereas the other cell compartments not. Under PT induction, calcein is released from mitochondria and becomes quenched into the cytosol by Co 2 þ , resulting in a decreased fluorescence. Taking advantage of this methodology, several groups reported that PT occurs in vivo in response to Ca 2 þ overload , after injury such as ischemia/reperfusion , oxidative stress (Nieminen et al., 1995 , chemotherapy (Poncet et al., 2003) and iron mitochondrial toxicity (Rauen et al., 2004) . In many of the above-mentioned models, an inhibition of the events that happen downstream to mitochondria membrane permeabilization are prevented by CsA and/ or BA.
Indications for a permeability transition pore role in apoptosis/necrosis By definition, apoptosis and necrosis represent two distinct modes of cell death that differ in the morphologic appearance of the dying cells . During necrosis, a marked loss of ATP (>25%) would be responsible for a defective assembly of the apoptosome and caspase activation (Adrain and Martin, 2001) , an inhibition of the plasma membrane Na þ / K þ ATPase leading to an ionic imbalance, water uptake (Barros et al., 2001) , poly (ADP-ribose) polymerase activation and NAD þ depletion (Los et al., 2002) . The two modes of cell death also differ in their physiological consequence. An apoptotic cell is usually rapidly phagocytosed by surrounded cells and does not induce an inflammatory response, whereas the appearance of necrotic cells trigger a concomitant local inflammation in vivo.
Does PTP opening occur in apoptosis as well in necrosis? Reportedly, cells can undergo a modification of DC m in the early steps of apoptosis, and also in necrosis (e.g. H 2 O 2 -induced necrosis (Troyano et al., 2003) and for a recent review, Zamzami et al., 2005) . Thus, in both types of cell death, this loss of DC m has been attributed to PT on the basis of pharmacological inhibitors such as CsA, BA, m-valCsA or sangliferin (see for herein references, Waldmeier et al., 2002) , yet a loss of DC m can also be induced by PTP-independent pathways (Finucane et al., 1999b; Ricci et al., 2003) . In apoptosis, three scenarios of mitochondrial membrane permeabilization have been reported: (i) PTP opening precedes the mitochondrial proapoptotic Bax translocation from the cytosol (Smaili et al., 2001; De Giorgi et al., 2002; Precht et al., 2005) , (ii) PTP opening occurs after the Bax activation and translocation from the cytosol to the mitochondrion (Tafani et al., 2001; Scorrano et al., 2003; Eldering et al., 2004; Weaver et al., 2005) and (iii) OM permeabilization, independently of the IM, relying on Bax and/or Bak and OM channels (Eskes et al., 1998; Finucane et al., 1999a; Piret et al., 2004) . To summarize, PTP opening has been observed in necrosis as well as in apoptosis. Depending on the model, PT can be a cause or a consequence of the activation of a lethal pathway and its real contribution can be solely defined by the capacity of specific inhibitors to abrogate (not only delay) the death, and by an extensive characterization of the mode of cell death with specific assays (phosphatidylserine exposure, subdiploidy and TUNEL assays).
Moreover, several authors proposed that the intensity of the insult, the duration of PTP opening and the level of ATP could determine the mode of cell death, apoptosis versus necrosis. Thus, a transient opening of PTP would be physiological and insufficient to trigger the cell death . In contrast, after an initial decrease in ATP level, a prolonged opening of PTP would be lethal and the maintenance of a high intracellular ATP level would favor apoptosis, whereas a low ATP level would orientate the cell death to necrosis (Leist et al., 1997; Lemasters et al., 1998; Halestrap, 2005) . In a pathologic situation, such as ischemia/reperfusion or acetaminophen overdose, two models that experienced a variation in ATP level, it has been shown that PTP can open in apoptotic cells, as well as in necrotic cells via CsA sensitivity Kon et al., 2004) . Therefore, (at least) three questions emerged concerning cancer cells: is PTP involved in the two types of cancer cell death, apoptosis versus necrosis and does the ATP level have an impact on the PTP opening susceptibility at the molecular level, given the fact that PTP composition could change in cancer cells? Finally, how can a sufficient amount of ATP be maintained for apoptosis induction under conditions when PTP is open?
Pharmacological inhibitor studies. Studies with pharmacological agents have been undertaken in many cancer cell lines. The effects of these agents are more or less reversible and usually led to a delay in cell death or a shift in the type of cell death from apoptosis to necrosis. It is important to note that depending on the doses, the majority of the pharmacological inhibitors can themselves be toxic and lead to cell death. Inhibitors targeting the opening of PTP appear to efficiently protect cells from all the consequences of chemotherapy-induced mitochondrial membrane permeabilization, that is, from the loss of DC m , the release of proapoptotic factors and caspase activation (Debatin et al., 2002) . On the contrary, caspase inhibitor effects proved to be more contrasted. Generally, their effects depend on the spectrum of targeted proteases, that is, initiator, executioner caspases, cathepsins or calpains. Thus, inhibitors targeting executioner caspases may be unable to prevent mitochondrial membrane permeabilization, whereas some inhibitors of initiator caspases (caspase 2 or 8) may be instrumental to inhibit PT , for instance in models of sulfur mustard-induced apoptosis (Sourdeval et al., in press ). Another class of potent inhibitors of chemotherapy-induced apoptosis regroups the reactive oxygen species (ROS) scavengers and agents that enhance the antioxidant cell defense, suggesting the involvment of PTP (Le . Indeed, many evidences have been accumulated to show that various pro-oxidant agents are able to promote PT and trigger cancer cell death (Buttke and Sandstrom, 1994) . In addition, the process of PT itself is a source of ROS that can amplify the signaling of apoptosis. The uncoupling of the mitochondria induced an arrest of oxidative phosphorylation and an arrest of the detoxification of ROS produced by auto-oxidation of the flavin component of complex I (NADH hydrogenase) and/or by auto-oxidation of the ubisemiquinone of complex III (Halliwell, 1999; Halliwell and Gutteridge, 1999) . Molecules produced refer to anion superoxide, radical hydroxyle and/or H 2 O 2 . Thus, as expected, many antioxidants, such as thiol protectors (GSH), vitamin E or trolox, butylated hydroxytoluene, were shown to inhibit the death induced by pro-oxidants stimuli as diverse as diamide, t-BHP, nitric oxide, peroxynitrite, 4-hydroxynonenal, at least in the prototypic cervix carcinoma cell line, HeLa cells (Kowaltowski et al., 1997; Costantini et al., 2000; Vieira et al., 2001 ). Nevertheless, above a quantitative threshold, it is generally admitted that pro-oxidant agents, as well as certain caspase inhibitors, favor the induction of necrosis.
In vitro reconstitution studies. The isolation and reconstitution of PTP has been a long-time interest for several teams. Indeed, the purification of PTP is the door to the identification of its precise composition. To date, the published protocols yield to a pre-purified/ enriched fraction solubilized by Triton X-100, which should be reconstituted immediately into liposomes to preserve the functionality of the complex (Beutner et al., 1996a; Brenner et al., 2000b) . These preparations contain at least the PTP components, but probably other mitochondrial and cytosolic contaminants. Several pharmacological reports support the similarity of the function of the pore in proteoliposomes and the pore in mitochondria (Beutner et al., 1996b; Marzo et al., 1998a, b; Brustovetsky et al., 2002; Deniaud et al., 2006) . Interestingly, Bax depletion selectively blocked Atrinduced liposomal membrane premeabilization, but not less specific stimuli such as t-BHP and diamide (Marzo et al., 1998a) . In isolated mitochondria and in artificial membranes, PT is inhibited by ATP and ADP (Halestrap et al., 1997b) , suggesting a putative protective effect of adenine nucleotides in vivo. This inhibition could be owing to a direct inhibition of ANT by ATP and ADP (Halestrap et al., 1997b; Brenner et al., 2000a; Belzacq et al., 2003) . This confirms the notion that during necrosis, under severe metabolic-stress conditions, with both ADP and ATP levels being low, PT might be favored. From Warburg's (1956) theory, it is known that cancer cells are highly glycolytic and that their mitochondrial production of ATP is impaired. Accordingly, fructose supplementation of ischemic cells to enhance glycolytic ATP generation can redirect the cell death to apoptosis .
Another approach has been to purify each component and to mix them to reproduce the function of the pore (Tanveer et al., 1996; Crompton et al., 1998) . This has been successfully applied to ANT, VDAC and CypD suggesting that VDAC constitutes the channel in the OM, ANT, the channel in the IM and CypD, the matrix partner, suggesting that these proteins constitutes the minimal PTP.
Genetic knockout models. Recently, experiments conducted on mice invalidated for both isoforms of ANT (ANT1 and 2) or CypD mitigated the findings on the implication of these proteins in PTP and in apoptosis (Baines et al., 2005; Basso et al., 2005; Nakagawa et al., 2005) . The mitochondria of mice knockout for ANT1 and ANT2 isoforms, still undergo calcium-induced PT, but at higher doses of calcium, suggesting that ANT would be dispensable for PT and for apoptosis induction by several stimuli (e.g. Fas, tumor necrosis factor (TNF)-a), but not for its own ligands (Atr, adenine nucleotides) (Kokoszka et al., 2004) . One hypothesis is that another IM protein (e.g. other mitochondrial carrier?) could complement the functions of ANT (Halestrap, 2004) . In addition, two independent studies of CypD knockout have shown that CypD is a component of PTP pore that is necessary for necrotic death by Ca 2 þ overload and oxidative stress in cell culture. However, CypD appeared to be required for cardiomyocyte and neuron apoptotic death (Schinzel et al., 2005) . These reports raised numerous critical questions, and are currently intensely debated (Halestrap, 2005; Schneider, 2005; Zamzami et al., 2005) .
Double knockout mice and cell lines, mouse embryonic fibroblasts (MEF) and HCT116, for Bax and Bak have been generated and found to be resistant to apoptosis induction by numerous intrinsic signals such as etoposide, staurosporine, UVC, thapsigargin and tunicamycin (Wei et al., 2001 ). The MEF model also revealed that proapoptotic PTP opening in response to arachidonic acid, as measured by calcein staining in MEF cells, is dependent on the endoplasmic reticulum (ER)-released calcium by Bax/Bak and on their mitochondrial localization (Scorrano et al., 2003) . Thus, BaxÀ/À/BakÀ/À cells may be useful to determine the inducers of PTP opening that require Bax/Bak or not, and study the dependence of necrosis to Bax/Bak. Indeed, one plausible hypothesis would be that PTP involved in necrosis should not require the participation of Bax/Bak.
Permeability transition pore independent models. Obviously, some models of apoptosis do not require the participation of PTP. This applies notably to type I cells that, in contrast to type II cells, undergo apoptosis following ligation of death receptor and are independent of the mitochondrial signaling pathway . In type I cells, the activation of the initiator caspase 8 is quantitatively sufficient to trigger the cascade of activation of caspases and the final steps of the cellular degradation. These cells usually do not exhibit typical mitochondrial alterations such as DC m loss and matrix swelling and are independent of the effects of the antiapoptotic proteins Bcl-2 and BclX L . A contrario, they would depend on the action of proapoptotic Bax and Bak (Wei et al., 2001 ). In addition, it is not clear whether the mitochondria of various tissues origins are all able to swell. The absence of mitochondrial swelling could be owing to the isolation procedure or a difference in colloido-osmotic environment of these mitochondria in cellulo. In addition, CypD deficiency results in a diminished cell death when induced by specific signals, in particular those that are mediated by a Ca 2 þ , with one study (Nakagawa et al., 2005) claiming that cypD mediates only necrosis, whereas another group observed an effect on apoptosis regulation (Baines et al., 2005) . The explanation for this discrepancy probably lies in the duration and strength of the stimulus used for cell death induction. Nevertheless, some signals for cell death such as staurosporine and TNF-a are unaffected by the absence of cypD (Baines et al, 2005; Nakagawa et al., 2005) . The results obtained so far from these CypD knockout mice do not support a role for Bcl-2 proteins in PT regulation (Baines et al., 2005) . Also, the work by Scorrano et al. (2003) showed that the role of Bax/Bak in PT is only indirect, via the regulation of calcium release from the ER. In fact, the PT-like response of the Bax/Bak DKO cells could be restored by overexpressing the ER calcium pumps SERCA; hence, PT could be observed in the absence of Bak and Bax. In conclusion, PTP is involved in many but not every scenario of apoptosis and in some instances, it might be responsible for amplification of the signal for cell death.
Subunits of the permeability transition pore: implications for cancer cells. Since the discovery of the PTP by Zoratti and Szabo (1995) , several observations have led to the proposal that several subunits could coexist, cooperating or functioning autonomously. This is supported by (1) the occurrence of multiple conductance states that is compatible with the existence of various subunits and/or different substates of the same channel Szabo, 1994, 1995) , (2) co-immunoprecipitation and co-purification studies that revealed that PTP members are engaged in molecular network of mitochondrial proteins and also with other organelles (Tanveer et al., 1996; Crompton et al., 1998; Verrier et al., 2004) , (3) native complex analysis by electrophoresis that identified at least six different subcomplexes containing ANT1 (Faustin et al., 2004) and (4) the redundancy of isoforms. Indeed, almost each PTP protein is encoded by several genes that could be differentially expressed in normal cells versus tumor cells (Azoulay-Zohar et al., 2004; Cesar Md Mde and Wilson, 2004; Palmieri, 2004) .
Thus, it appears that PTP mitochondrial proteins could be organized in several networks, some of them being dedicated to the energetic metabolism maintenance, and other to the control of the mode of cell death (Figure 2 ). Owing to changes in protein-protein interactions, some PTP proteins may switch their involvment in different networks. This is, notably, illustrated by ANT that allows the adenine nucleotide exchange (metabolic network) and controls the permeability of the IM (cell death network), and by VDAC in the OM that allows the free diffusion of solutes (metabolic network) and modulates apoptosis via Bak inhibition (cell death network) (for a review, see Rostovtseva et al., 2005) . It is important to note that the two proteins, ANT and VDAC, are tightly regulated positively or negatively by pro and antiapoptotic proteins from the oncoproteins of the Bax/Bcl-2 family (Marzo et al., 1998a; Narita et al., 1998; Vander Heiden and Thompson, 1999) .
The permeability transition pore in cancer
Various steps during tumorigenesis induce apoptosis such as oncogene activation, loss of cell-cell or cellmatrix attachment during metastasis formation, growth factor deprivation and a hypoxic environment (Townson et al., 2003) . Moreover, apoptosis induction is the principal mode of action for chemotherapeutic compounds. The acquired unresponsiveness of cancer cells to these signals is supposed to be one of the hallmarks of tumor cells (Hanahan and Weinberg, 2000) with one school of thought even proclaiming it to be -besides unrestricted proliferation -the most important feature of cancer cells (Green and Evan, 2002) . In any case, apoptosis repression is for sure fundamentally underlying tumorigenesis and constitutes one of the major problems in cancer treatment. Hence, a protein complex such as the PTP that mediates many proapoptotic signals (see above: friend and foe) is a prime target for inhibition in order to facilitate the unrestrained proliferation of malignant cells. In fact, although the involvement of the PTP in cell death during cardiac hypoxia/reperfusion has been established for a long time (Crompton et al., 2002) , various recent evidence points to a prominent role in another major disease scenario: in tumorigenesis.
Specific inducers of the permeability transition pore are activated during tumorigenesis
The enumeration of apoptosis scenarios below reveals that signals known to activate the PTP for apoptosis are unleashed in tumor cells. However, as the rate of proliferation supersedes the rate of cell attrition in tumors, these proapoptotic signals must be inhibited. This can be accomplished upstream of the PTP by, for example, reducing the concentration of ROS through antioxidants. However, as many of these signals can still be detected in tumor cells, a more proximal inhibition near or at the PTP is likely. Consequently, the examples below represent circumstantial evidence for a role of the PTP in apoptosis inhibition during tumorigenesis.
Hypoxia is a condition of reduced oxygen supply that most tumor cells encounter in the primary tumor mass but also during metastasis formation distant from their site of origin before the growth of blood vessels (angiogenesis) sets in. Hypoxia activates the PTP, probably by upregulating specific proapoptotic factors such as the Bcl-2 family members BNIP and NIX through the hypoxia-inducible factor (HIF) transcription factor (Vande Velde et al., 2000; Sowter et al., 2001; Kubasiak et al., 2002) . Exactly how tumor cells evade hypoxia is presently an intensely investigated question. It seems that several soluble factors such as vascular endothelial growth factor are released from tumor cells that further the growth of blood vessels. However, this does not completely preclude hypoxic conditions for tumor cells. At least for short periods of time, these aberrant cells have to withstand such an environment. In fact, although hypoxia is an apoptosis signal in many normal cells, in tumor cells, it is specifically inhibited and the survival under hypoxic conditions is one of the distinguishing features of cancer cells (Harris, 2002) . In pancreas cancer, it has been shown that HIF can no longer activate the BNIP3 promotor owing to its hypermethylation (Okami et al., 2004) , but the reason for survival under hypoxia is, in most cases, not completely understood. Given the sensitivity of the PTP for this condition, a role of the PTP can be envisaged and needs to be more closely investigated in the future.
We recently found that in some scenarios of anoikis, the PTP is likewise activated (CB, unpublished). Anoikis is the kind of apoptosis that is induced during the loss of cell attachment, which occurs before the dissemination of tumor cells from their site of origin during metastasis formation. A pivotal role in this apoptosis process seems to be occupied by the proapoptotic Bcl-2 family members Bid (Valentijn and Gilmore, 2004) and Bax (Valentijn et al., 2003) , which can directly interact with components of the PTP (Marzo et al., 1998a; Zamzami et al., 2000) . Inhibition of apoptosis by anoikis is a requirement to allow the colonization of distant organs. Hence, also in this scenario, the PTP could be a major target for apoptosis inhibition in metastasis-forming tumor cells.
The breakdown of the OM releases cytochrome c, thereby inhibiting the respiratory chain, generating ROS and contributing to the activation of the PTP. The PTP, conversely, also aids in the breakdown of this mitochondrial membrane barrier (see above: friend and foe). Thus, the disruption of the OM is both cause and consequence of PTP activation. It is known that tumor cells are overall more resistant to the breakdown of the OM (Green and Evans, 2002) . Hence, it could be speculated that the PTP is responsible for this defect.
At low doses, ROS play an important role in the signaling for proliferation but -at higher concentrations -also for cell death (Pelicano et al., 2004) . It is known that tumor cells generate excessive amounts of ROS and are therefore permanently under oxidative stress (Pelicano et al., 2004) . Reactive oxygen species are also one of the most efficient activators of the PTP for apoptosis (Petronilli et al., 1994) . Because of this and as many Multiple Signaling Pathway PTP-anti-apoptotic interactor PTP-pro-apoptotic interactor Figure 2 Putative model of the regulation of protein-protein interaction within PTP during apoptosis. Upon physiological conditions, PTP is implicated in the mitochondrial homeostasis and metabolism. Therefore, its members are involved in direct or indirect interactions with proteins belonging to the general metabolism and to multiple signaling pathways. These interactions allow a crosstalk between PTP-dependent regulation of mitochondrial membrane permeability and calcium fluxes (IP3R and RYR channels), respiration (NADH ubiquinione reductase), ion transport (UCP, chloride channel), redox balance (GST and sulfurtransferase), as well as phosphorylation/dephosphorylation pathways (kinase/phosphatase). Upon apoptosis induction, some antiapoptotic (e.g. Bcl-2) interactions are lost and other proapoptotic interactions (e.g. Bax) are increased to favor the apoptotic process.
APOPTOSIS SIGNALING PHYSIOLOGICAL CONDITIONS
anticancer drugs induce the formation of ROS and apoptosis, it is not surprising that tumor cells have found ways to cope with ROS generation. Drugresistant tumor cells, for example, contain increased glutathione and thioreoxin level (Dvorakova et al., 2002; Biaglow and Miller, 2005) , two crucial antioxidants in the cells. Also, manganese superoxide dismutase is found upregulated in cancers and seems to protect them against ROS (Pani et al., 2004) . Reactive oxygen species are, however, not entirely detoxified in tumor cells as their increased concentrations can still be detected. This again calls for an inhibition of the PTP in those malignant cells.
Numerous reports show that upon ROS formation, Ca 2 þ is released from intracellular stores such as the ER and ingresses from the extracellular environment (Chakraborti et al., 1999; Ermak and Davies, 2002) . Thus, a cell -such as a tumor cell -that is under oxidative stress is also under increased danger to increase the cytosolic calcium. As described in (see above: friend and foe), Ca 2 þ is a very potent stimulus for the PTP. It was recently revealed that tumor cells resistant to chemotherapeutics more efficiently sequester Ca 2 þ and show a reduced release of this ion from intracellular storage sites upon apoptosis induction (Chandra et al., 2002) . Consequently, these tumor cells are less sensitive to the stimulus exerted by Ca 2 þ . Also, it has been proposed that an impaired storage of calcium in -and therefore a reduced release from -the ER is linked to the transition of androgen-dependent to hormone-independent prostrate cancer cells and the reduced apoptosis seen in androgen-independent tumor cells (Prevarskaya et al., 2004) . Again, the causes for resistance of calcium-induced apoptosis can be expected to be manifold and the PTP -with its exquisite sensitivity to detect increased calcium concentrationsis a potential prime target for inhibition.
Subunits of the permeability transition pore are differentially expressed in tumor cells
The above-mentioned proapoptotic signals set a conceptual framework for postulating the inhibition of the PTP as a mediator of tumor growth. The most direct indication for a role of the PTP in tumorigenesis is the substantial body of data that has accumulated over the years showing that specific components of this protein complex are up or downregulated.
The PBR, for example, is overexpressed in a number of neoplastic tissues and tumor cell lines. In particular, breast, ovarian, hepatic and colon carcinomas show increased expression when compared with their normal cells. One study found a correlation of PBR upregulation with the aggressiveness of both breast tumor cells and breast tumor tissue (Hardwick et al., 1999) . Ovarian cancer, another tumor from estrogen-sensitive tissue, is likewise characterized by a three-to fivefold upregulation of PBR (Katz et al., 1990) . Using immunocytochemical staining, other workers found that the augmentation of PBR corresponds to a lower life expectancy of patients with astrocytomas (Miettinen et al., 1995) . One of the most frequent cancers, colon cancer, also displays an increase in the PBR protein (Katz et al., 1990) , as do hepatomas (Venturini et al., 1998) . Also, up to 86% of all adenomas have PBR overexpressed and those cancers with enhanced PBR levels form statistically more frequently metastases (Maaser et al., 2005a, b) . In line with these findings, ligands for PBR reconstitute the sensitivity to apoptosis induction in resistant cell lines (Decaudin et al., 2002) . However, although these data indicate a clear correlation of progressive tumorigenesis with the upregulation of PBR, the in vivo situation seems to be more complicated. In skin cancer, for example, PBR is downregulated (Morgan et al., 2004) and a reduction of PBR by antisense increased -not decreasedtumorigenicity in two studies (Weisinger et al., 2004; Levin et al., 2005) . Consequently, one must keep in mind that the data above establish a correlation between the expression level of PBR and progressive tumorigenesis and not necessarily a causative relation.
Hexoikinase II has been shown to inhibit apoptosis by the PTP by blocking the access of Bax to the PTP. Only after its displacement has Bax access to VDAC and can activate the PTP (Pastorino et al., 2002) . In keeping with its activity to inhibit the PTP by protein-protein interactions, HKII is found upregulated in tumors (Shinohara et al., 1991; Rempel et al., 1996; AzoulayZohar et al., 2004) . One study detected this enzyme in 45% of all breast tumor samples investigated (Gudnason et al., 1984) . Besides the activation of the promotor of the HKII gene, an amplification of the gene has also been observed (Rempel et al., 1996) . This upregulation of HKII could also -at least partially -explain the classic observation that tumor cells increase glycolysis despite the presence of molecular oxygen (the so-called Warburg effect). The HKII promotor contains an HIFbinding element. This transcription factor is activated under hypoxic conditions and has been shown to inhibit apoptosis under these circumstances. Thus, it is conceivable that HKII expression by HIF contributes to this. In fact, a correlation has been detected between the presence of HIF and the upregulation of HKII (Yasuda et al., 2004) . This is to our knowledge so far the most direct link between the tumorigenesis scenarios enumerated above and the PTP inhibition by a specific component of the PTP.
Recently, we and others found that CypD is an inhibitor of the PTP in tumor cells (Lin and Lechleiter, 2002; Li et al., 2004; Schubert and Grimm, 2004) . Using a blot array that compared malignant with normal tissue from various patients, it was observed that cypD is upregulated in cancer cells from estrogen-responsive tissues such as ovary, uterus and ovary (Schubert and Grimm, 2004) . With the established importance of estrogen, especially in the early phases of breast tumorigenesis, it is not unexpected that tumors from other estrogen-sensitive tissues likewise show upregulated CypD.
Creatine kinase I (CKI) was likewise identified by us as an inhibitor of the PTP (Schubert and Grimm, 2004) . In line with this, mitochondrial CK is found to be upregulated in various tumors (DeLuca et al., 1981; Pratt et al., 1987; Baines et al., 2005; Nakagawa et al., 2005) and was detected in the first tumor cell line from Hodgkin's lymphoma (Nakagawa et al., 2005) .
Also, VDAC isoforms have been found to be increased in some tumors (Shinohara et al., 2000) . The relevance of this finding for tumorigenesis and PTP inhibition, however, is not clear as one report claims that VDAC-2 inhibits the proapoptotic Bcl-2 protein Bak , whereas another study found that VDAC-2 can directly induce apoptosis (Zaid et al., 2005) .
Various reports observed an increase of ANT-2 in renal tumors and various other cancer (Faure Vigny et al., 1996; Giraud et al., 1998; Bonod-Bidaud et al., 2001) . This antiporter, in contrast to its close relative, ANT-1, is not activating the PTP and not inducing apoptosis when overexpressed (Bauer et al., 1999) . Given the increased energy requirement of fast proliferating tumor cells, it could be speculated that the transport of ATP from its site of synthesis in mitochondria to the cytosol is performed by this upregulated ANT-2 without sensitizing the cells for apoptosis. The low abundance of ANT-2 in normal cells even led to the speculation that it would constitute a drug target.
Bax is occupying a central position in the regulation of the apoptosis machinery as evidenced by the almost complete absence of cell death upon its (and Bak's) inactivation (Wei et al., 2001 ). This protein is also an important modulator of the PTP (see above: friend and foe). In accordance, it has been found to be frequently mutated in T-cell leukemias (Meijerink et al., 1998; Catasus et al., 2000; Inoue et al., 2001) , gastric cancers (Ionov et al., 2000) and frame shift mutations have been found in colon carcinomas (Rampino et al., 1997) . Other Bcl-2 proteins that regulate the activity of the PTP are upregulated in tumors. In particular, the founding member Bcl-2 is increased in many tumors such as hematological malignancies, including follicular lymphomas, chronic lymphocytic and acute myelogenous leukemias (Kornblau et al., 1999) and many other types of cancer (Manion and Hockenbery, 2003) .
So, it seems that tumorigenesis is accompanied by a differential expression of subunits of the PTP. Can we find a scientific rationale for this? Our speculation is that this serves to inhibit this protein complex for apoptosis induction by using specific interactions among its protein components. In fact, an overview of apoptosis signaling pathways reveals that mostly protein-protein interactions direct apoptosis. This is in contrast to cellular processes such as the cell cycle whose individual steps in the signaling cascade are predominantly governed by protein phosphorylation. We propose here that many, if not most, elements of the apoptosis machinery have been developed during evolution to respond to cell stress. Apoptosis regulators can even be found in primitive organisms such as yeast (Madeo et al., 2004) , which have no need for developmental cell death. Only later in evolution were these proteins recruited to control what is now known as 'Programmed Cell Death' in order to execute cell death during development of multi-cellular organisms. Cell stress, is changing many parameters in the cell such as ion and ROS concentration , to which enzymes are very sensitive. This could be the reason why mostly protein-protein interactions, which are stable enough to signal even under such stress, are employed in apoptosis. Thus, the composition and the interactions within many apoptosis regulatory complexes are controlled by the relative abundance of their subunits, which decide whether a pro-or an antiapoptotic signal is created. The DISC complex, for example, that is activated by the Fas ligand comprises both proand antiapoptotic subunits and their relative representation in this complex determines its signaling for apoptosis (Peter and Krammer, 2003) . Other examples for this principle are the Bap31 complex (Mund et al., 2003) and the apoptosome (Yang and Cortopassi, 1998) . Hence, we hypothesize that the PTP is likewise regulated by the relative abundance of its components and the resulting subunit composition. This is, as we think, the reason why the relative abundance of the PTP subunits is found different in normal versus transformed cells.
Accordingly, we set up a system to study the subunit composition of the PTP. Using apoptosis by etoposide, an inhibitor of topoisomerase II, as a model system, we found that upon apoptosis induction spcific proteins are recruited to this complex, whereas others are released (Verrier et al., 2004) . The proapoptotic protein Bax, for example, associates with the PTP upon cell death induction. In parallel, the interaction of the antiapoptotic Bcl-2 with the PTP was found reduced. The core of this protein complex, the interaction between VDAC, ANT-1 and Cyp D, however, remained unchanged. Interestingly, an inhibitor of PTP (CsA), of mitochondrial translocation of Bax (e.g. furosemide) or of pancaspases (e.g. z-VDAD) abolished the changes in the ANT interactome and the cell death, demonstrating the link between protein-protein interactions and apoptosis (Verrier et al., 2004) . As the activation of the PTP comprises a conformation change of the ANT-1, this result implicates that the observed change in the composition of the PTP could be a prerequisite for this conformation change. Importantly, we also isolated novel interactors of the ANT-1 complex in this study such as gluthatione S-transferase that functions as repressor of the ANT pore function and is also overexpressed in many tumor cells (Hayes and Pulford, 1995) .
Given the role of the PTP in necrosis, it will be especially interesting to compare this with the situation during apoptosis. Our expectation is that, as this kind of cell death is rapid and uncontrolled, the composition changes of the PTP should be limited.
Based on the prominent role of protein-protein interactions in apoptosis regulation and the fact that most mediators of apoptosis induce cell death upon overexpression, we established a screen for apoptosisinducing genes Schoenfeld et al., 2004) . Interestingly, with ANT-1 and VDAC, two components of the PTP were isolated that induce an especially strong and fast apoptosis. In keeping with our approach to target specific protein-protein interactions, we overexpressed additional components of the PTP and observed apoptosis induction and inhibition by particular subunits of this protein complex. Adenine nucleotide translocase-1, for example, but not the almost identical ANT-2, was able to induce apoptosis (Bauer et al., 1999) . Various control experiments indicated that this was not owing to ANT-1 forming an unspecific pore on its own. Instead, our model postulates that ANT-1 can titrate out inhibitors from the endogenous PTP, thereby activating this protein complex for cell death. In fact, the overexpression of Cyp D has been shown to inhibit apoptosis by several groups (Lin and Lechleiter, 2002; Li et al., 2004; Schubert and Grimm, 2004) .
Interestingly, the data from mouse knockouts of CypD suggest pro-, rather than antiapoptotic, activities of this protein (Baines et al., 2005; Nakagawa et al., 2005) . This could be owing to differences in the experimental settings or cell type-specific effects.
Open questions and perspectives
In this review, we recapitulated and discussed the evidences that claim for a role of PTP in cancer cell death. The deregulation of expression of PTP members and of signaling pathways that converge on the Belzacq et al. (2001b) Carbonyl scavengers Antimelanoma activity Induces CsA-dependent PTP opening Wondrak et al. (2005) Abbreviations: ANT, adenine nucleotide translocase; CsA, cyclosporin A; GSAO, 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide; MMP, mitochondrial membrane permeabilization; PBR, peripheral benzodiazepine receptor; PTP permeability transition pore.
PTP and cancer cell death C Brenner and S Grimm inhibition of PTP function in these cells are currently the major clues involving PTP, yet other events, such as functional mutation or gene translocation have not been investigated so far but are likewise possibly underlying causes. Recent progress in the understanding of PTP structure and function relationships will have important implication in the development and management of cancer therapy. The permeability transition pore itself can be considered as a potential therapeutic target. This has been recently illustrated with the protection of mice from three acute pathologies by a pharmacological agent, Nelfinavir via an inhibition of apoptosis in vivo (Weaver et al., 2005) . The compound co-administrated with ritonavir protects mice from Fas-induced hepatitis, septic shock and ischemia/reperfusion damage provoked by middle-cerebral arteria occlusion. This agent is already used in highly antiretroviral therapy in AIDS patients, underscoring the feasibility of a human trial. Hence, it becomes plausible to envisage that such drug (in a proapoptotic version) could be developed for the treatment of chronic pathologies such as cancer.
The holy grail of all drug research against cancer is to find compounds specific for transformed cells. Can the PTP with its documented different composition in cancer cells be targeted for this aim? Recently, the plant lipids jasmonates were discovered to act only on transformed tumor cells for apoptosis induction. Interestingly, they target mitochondria and in particular the PTP for this (Rotem et al., 2005) . Although the exact mechanism of how the PTP is activated in a tumorspecific way in this scenario is still unknown, it is a proof-of-concept that PTP can mediate a tumor-specific signal for the destruction of malignant cells. In Table 1 , we have listed some of the proapoptotic compounds and biologicals that act on the PTP. Some of these compounds are already used in clinics but others have been tested onto cancer cell lines in vitro. We hope that some of these or future drugs targeting the PTP will prove to be efficient in clinic trials for cancer treatment.
Abbreviations ADP, adenosine diphosphate; ANT, adenine nucleotide translocase; ATP, adenosine 5 0 triphosphate; Atr, atractyloside; BA, bongrekic acid; CK, creatine kinase; CsA, cyclosporin A; CypD, Cyclophilin D; DC m , inner transmembrane potential; HK, hexokinase; IM, inner membrane; MEF, mouse embryonic fibroblasts; OM, outer membrane; PBR, peripheral benzodiazepine receptor; PT, permeability transition; PTP, permeability transition pore; ROS, reactive oxygen species; t-BHP, tert-butylhydroperoxide; TNF, tumor necrosis factor; VDAC, voltage-dependent anion channel.
